초록 ▼

The invention describes novel formulations of nonsteroidal anti-inflammatory drugs (NSAIDs) based on complex aggregates with at least three amphipatic components suspended in a suitable, e.g. pharmaceutically acceptable, polar liquid medium. A suitably ionised NSAID is one of the two, amongst said t

The invention describes novel formulations of nonsteroidal anti-inflammatory drugs (NSAIDs) based on complex aggregates with at least three amphipatic components suspended in a suitable, e.g. pharmaceutically acceptable, polar liquid medium. A suitably ionised NSAID is one of the two, amongst said three, components that tends to destabilise lipid membranes, the other system component with such activity being typically a surfactant. In contrast, the remaining amongst said at least three amphipatic components typically forms a stable lipid membrane on it's own. An essential characteristics of the resulting, relatively large, aggregates is an improved ability to penetrate pores, in a semi-permeable barrier, at least 30%, and often much smaller than the average diameter of the complex aggregate. This enables said aggregates to mediate NSAID transport through semi-permeable barriers including mammalian skin. As a result of the skin penetration by NSAID loaded large aggregates, the drug delivered transcutaneously with such carriers gets deeper into the tissue than the corresponding NSAID from a solution on the skin surface. This is believed to be due to the special ability of suitable large carriers to bypass the local sink of blood capillaries at the epidermal-dermal junction in the skin. The carrier-mediated delivery of locally applied NSAIDs thus allows therapy of deep tissues under the drug administration site, which is medically highly desirable.

대표청구항 ▼

The invention claimed is: 1. A vesicular composition comprising: 1) vesicles having a lipid bilayer and consisting essentially of: i) a phosphatidylcholine; ii) a polyethyleneglycol-sorbitan-monooleate, a polyoxyethylene-oleoyl ether, or a nonaethyleneglycoloctylphenyl ether surfactant; and iii) a

The invention claimed is: 1. A vesicular composition comprising: 1) vesicles having a lipid bilayer and consisting essentially of: i) a phosphatidylcholine; ii) a polyethyleneglycol-sorbitan-monooleate, a polyoxyethylene-oleoyl ether, or a nonaethyleneglycoloctylphenyl ether surfactant; and iii) a salt of an NSAID wherein said NSAID is diclofenac, ibuprofen or ketoprofen; and 2) a pharmaceutically acceptable, polar liquid medium, wherein the phosphatidylcholine and the surfactant of the vesicles are present in a molar ratio of between about 20/1 and about 7.5/1, the molar ratio of phosphatidylcholine to NSAID is between about 10/1 to about 1/1, the lipid bilayer is in the fluid lamellar phase, and the pH of the composition is above the pKa of the NSAID. 2. The composition of claim 1, wherein the phosphatidylcholine is from soy bean, coconut, olive, safflower, or sunflower, linseed, evening primrose, primrose, or castor oil. 3. The composition of claim 1, wherein the total dry mass of the phosphatidylcholine, the surfactant, and the NSAID is between 0.01 weight-% and 50 weight-% of the composition. 4. The composition of claim 1, further comprising a lower aliphatic alcohol. 5. The composition of claim 4, wherein the alcohol is n-propanol, isopropanol, 2-propanol, n-butanol, 2-butanol, 1,2-propanediol, 1,2-butanediol, or ethanol. 6. The composition of claim 1, wherein the pH of the composition is between 6.4 and 8.3. 7. The composition of claim 1, wherein the ionic strength of the composition is between 0.005 and 0.3. 8. The composition of claim 1, wherein the viscosity of the composition is between 50 mPas and 30,000 mPas. 9. A method for treating peripheral pain or inflammation comprising applying the composition of claim 1 to the skin of a warm blooded mammal. 10. A non-occlusive patch comprising the composition of claim 1. 11. The composition of claim 1, wherein the total dry mass of, the polyethyleneglycol-sorbitan-monooleate, polyoxyethylene-oleoyl ether, or nonaethyleneglycol octylphenyl ether surfactant; and the NSAID is between 0.01 weight-% and 50 weight-%. 12. The composition of claim 1, wherein the phosphatidylcholine is soy phosphatidylcholine or egg lecithin. 13. The composition of claim 1 wherein the salt of the NSAID is the sodium salt of ketoprofen. 14. The composition of claim 1, wherein the phosphatidylcholine is soy phosphatidylcholine, the surfactant is polyethyleneglycol-sorbitan-monooleate, and the salt of the NSAID is the sodium salt of ketoprofen. 15. The composition of claim 1, wherein the molar ratio of phosphatidylcholine to NSAID is between about 3/1 to about 1/1. 16. The composition of claim 15, wherein the molar ratio of phosphatidylcholine to NSAID is between about 2.5/1 to about 1/1. 17. The composition of claim 16, wherein the molar ratio of phosphatidylcholine to NSAID is between about 2/1 to about 1/1. 18. The composition of claim 17, wherein the molar ratio of phosphatidylcholine to NSAID is about 1/1. 19. The composition of claim 14, wherein the molar ratio of phosphatidylcholine to NSAID is between about 3/1 to about 1/1. 20. The composition of claim 19, wherein the molar ratio of phosphatidylcholine to NSAID is between about 2.5/1 to about 1/1. 21. The composition of claim 20, wherein the molar ratio of phosphatidylcholine to NSAID is between about 2/1 to about 1/1. 22. The composition of claim 21, wherein the molar ratio of phosphatidylcholine to NSAID is about 1/1. 23. The method of claim 9, wherein the molar ratio of phosphatidylcholine to NSAID is between about 3/1 to about 1/1. 24. The method of claim 23, wherein the molar ratio of phosphatidylcholine to NSAID is between about 2.5/1 to about 1/1. 25. The method of claim 24, wherein the molar ratio of phosphatidylcholine to NSAID is between about 2/1 to about 1/1. 26. The method of claim 25, wherein the molar ratio of phosphatidylcholine to NSAID is about 1/1. 27. A method for treating peripheral pain or inflammation comprising applying the patch of claim 1, to the skin of a warm blooded mammal. 28. The method of claim 27, wherein the molar ratio of phosphatidylcholine to NSAID is between about 3/1 to about 1/1. 29. The method of claim 28, wherein the molar ratio of phosphatidylcholine to NSAID is between about 2.5/1 to about 1/1. 30. The method of claim 29, wherein the molar ratio of phosphatidylcholine to NSAID is between about 2/1 to about 1/1. 31. The method of claim 30, wherein the molar ratio of phosphatidylcholine to NSAID is about 1/1. 32. The composition of claim 1, wherein the pH of the composition is between 0.2 and 2.2 pH units above the pKa of the NSAID. 33. The composition of claim 32, wherein the pH of the composition is between 0.5 and 1.9 pH units above the pKa of the NSAID. 34. The composition of claim 33, wherein the pH of the composition is between 0.8 and 1.6 pH units above the pKa of the NSAID. 35. The composition of claim 1, wherein the phosphatidylcholine is from egg or soya beans. 36. The composition of claim 1, further comprising a thickening agent; an antioxidant, or a microbicide. 37. The composition of claim 1, wherein the phosphatidylcholine and the surfactant are present in a molar ratio of between about 14/1 and about 10/1. 38. The composition of claim 1, wherein the pH is between 0.2 and 2.2 pH units above the pKa of the NSAID. 39. A method for treating peripheral pain or inflammation comprising applying the composition of claim 38, to the skin of a warm blooded mammal. 40. The method of claim 39, wherein the pH is between 0.2 and 2.2 pH units above the pKa of the NSAID. 41. A vesicular composition comprising: 1) vesicles consisting essentially of: i) a phosphatidylcholine; ii) a polyethyleneglycol-sorbitan-monooleate, a polyoxyethylene-oleoyl ether, or a nonaethyleneglycoloctylphenyl ether surfactant; and iii) a salt of an NSAID wherein said NSAID is diclofenac, ibuprofen or ketoprofen; and 2) a pharmaceutically acceptable, polar liquid medium, wherein the phosphatidylcholine and the surfactant of the vesicles are present in a molar ratio of between about 20/1 and about 7.5/1, the molar ratio of phosphatidylcholine to NSAID is between about 10/1 to about 1/1, the vesicles are capable of penetrating a barrier with pores having an average pore diameter at least 50% smaller than the average vesicle diameter before the penetration, and the pH of the composition is above the pKa of the NSAID. 42. The composition of claim 41, wherein the phosphatidylcholine is from soy bean, coconut, olive, safflower, or sunflower, linseed, evening primrose, primrose, or castor oil. 43. The composition of claim 41 wherein the total dry mass of the phosphatidylcholine, the surfactant, and the NSAID is between 0.01 weight-% and 50 weight-% of the composition. 44. The composition of claim 41, further comprising a tower aliphatic alcohol. 45. The composition of claim 44, wherein the alcohol is n-propanol, isopropanol, 2-propanol, n-butanol, 2-butanol, 1,2-propanediol, 1,2-butanediol, or ethanol. 46. The composition of claim 41, wherein the pH of the composition is between 6.4 and 8.3. 47. The composition of claim 41, wherein the ionic strength of the composition is between 0.005 and 0.3. 48. The composition of claim 41, wherein the viscosity of the composition is between 50 mPa s and 30,000 mPa s. 49. The composition of claim 41, wherein the total dry mass of, the phosphatidylcholine; the polyethyleneglycol-sorbitan-monooleate, polyoxyethylene-oleoyl ether, or nonaethyleneglycol octylphenyl ether surfactant; and the NSAID is between 0.01 weight-% and 50 weight-%. 50. The composition of claim 41, wherein the phosphatidylcholine is soy phosphatidylcholine or egg lecithin. 51. The composition of claim 41 wherein the salt of the NSAID is the sodium salt of ketoprofen. 52. The composition of claim 41, wherein the molar ratio of phosphatidylcholine to NSATD is between about 3/1 to about 1/1. 53. The composition of claim 52, wherein the molar ratio of phosphatidylcholine to NSAID is between about 2.5/1 to about 1/1. 54. The composition of claim 53, wherein the molar ratio of phosphatidylcholine to NSAID is between about 2/1 to about 1/1. 55. The composition of claim 54, wherein the molar ratio of phosphatidylcholine to NSAID is about 1/1. 56. The composition of claim 41, wherein the phosphatidylcholine is soy phosphatidylcholine, the surfactant is polyethyleneglycol-sorbitan-monooleate, and the salt of the NSAID is the sodium salt of ketoprofen. 57. The composition of claim 56, wherein the molar ratio of phosphatidylcholine to NSAID is between about 3/1 to about 1/1. 58. The composition of claim 57, wherein the molar ratio of phosphatidylcholine to NSAID is between about 2.5/1 to about 1/1. 59. The composition of claim 58, wherein the molar ratio of phosphatidylcholine to NSAID is between about 2/1 to about 1/1. 60. The composition of claim 59, wherein the molar ratio of phosphatidylcholine to NSAID is about 1/1. 61. The composition of claim 41, wherein the pH of the composition is between 0.2 and 2.2 pH units above the pKa of the NSAID. 62. The composition of claim 61, wherein the pH of the composition is between 0.5 and 1.9 pH units above the pKa of the NSAID. 63. The composition of claim 62, wherein the pH of the composition is between 0.8 and 1.6 pH units above the pKa of the NSAID. 64. The composition of claim 41, wherein the phosphatidylcholine is from egg or soya beans. 65. The composition of claim 41, further comprising a thickening agent, an antioxidant, or a microbicide. 66. The composition of claim 41, wherein the phosphatidylcholine and the surfactant are present in a molar ratio of between about 14/1 and about 10/1. 67. The composition of claim 66, wherein the pH is between 0.2 and 2.2 pH units above the pKa of the NSAID. 68. A method for treating peripheral pain or inflammation comprising applying the composition of claim 41 to the skin of a warm blooded mammal. 69. The method of claim 68, wherein the molar ratio of phosphatidylcholine to NSAID is between about 3/1 to about 1/1. 70. The method of claim 69, wherein the molar ratio of phosphatidylcholine to NSAID is between about 2.5/1 to about 1/1. 71. The method of claim 70, wherein the molar ratio of phosphatidylcholine to NSAID is between about 2/1 to about 1/1. 72. The method of claim 71, wherein the molar ratio of phosphatidylcholine to NSAID is about 1/1. 73. A method for treating peripheral pain or inflammation comprising applying the composition of claim 66 to the skin of a warm blooded mammal. 74. The method of claim 73, wherein the pH is between 0.2 and 2.2 pH units above the pKa of the NSAID. 75. A non-occlusive patch comprising the composition of claim 41. 76. A method for treating peripheral pain or inflammation comprising applying the patch of claim 75 to the skin of a warm blooded mammal. 77. The method of claim 76, wherein the molar ratio of phosphatidylcholine to NSAID is between about 3/1 to about 1/1. 78. The method of claim 77, wherein the molar ratio of phosphatidylcholine to NSAID is between about 2.5/1 to about 1/1. 79. The method of claim 78, wherein the molar ratio of phosphatidylcholine to NSAID is between about 2/1 to about 1/1. 80. The method of claim 79, wherein the molar ratio of phosphatidylcholine to NSAID is about 1/1.